Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
| Revenue (TTM) | $2.54B |
| Gross Profit (TTM) | $2.43B |
| EBITDA | $1.56B |
| Operating Margin | 19.80% |
| Return on Equity | 14.00% |
| Return on Assets | 5.09% |
| Revenue/Share (TTM) | $5.82 |
| Book Value | $15.53 |
| Price-to-Book | 3.82 |
| Price-to-Sales (TTM) | 13.55 |
| EV/Revenue | 23.09 |
| EV/EBITDA | 34.18 |
| Quarterly Earnings Growth (YoY) | -46.30% |
| Quarterly Revenue Growth (YoY) | 16.50% |
| Shares Outstanding | $445.28M |
| Float | $415.39M |
| % Insiders | 6.49% |
| % Institutions | 87.31% |
Volatility is currently contracting
Royalty Pharma (RPRX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, RPRX crossed above the 20-day moving average, suggesting a short-term bullish trend.
NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $100 million in funding to Zealand Pharma in exchange for Zealand Pharma's economics related to rusfertide (PTG-300), a potential first-in-class therapy for polycythemia vera, a rare and chronic blood disorder.
Company announcement – No. 38 / 2026 Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide Zealand Pharma will receive USD 100 million for the sale of its economic interests related to rusfertide, including royalty rights on the potential future global net sales of rusfertide.
Royalty Pharma NASDAQ: RPRX raised its 2026 outlook for the second consecutive quarter after reporting higher second-quarter royalty receipts, continued capital deployment and progress across its development-stage pipeline.
Royalty Pharma plc (RPRX) Q2 2026 Earnings Call Transcript
Although the revenue and EPS for Royalty Pharma (RPRX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Royalty Pharma (RPRX) came out with quarterly earnings of $1.32 per share, beating the Zacks Consensus Estimate of $1.27 per share. This compares to earnings of $1.14 per share a year ago.
Portfolio Receipts growth of 6% to $773 million; Royalty Receipts growth of 14% Net cash provided by operating activities of $728 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,400 million to $3,500 million NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts. “Royalty Pharma delivered strong second quarter results with Royalty Receipts growth of 14%,” said Pablo Legorreta, Royalty Pharma's Chief Executive Officer and Chairman of the Board.
Beyond analysts' top-and-bottom-line estimates for Royalty Pharma (RPRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RPRX and any ticker you trade — then tracks every position and per-strategy win rate.
